Abgenomics Cooperatief U.A.
Records under this name other than patents Abgenomics Cooperatief U.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Abgenomics Cooperatief U.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,604,800 | ANTI-PSGL-1 Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 11,897,964 | ANTI-PSGL-1 Antibodies and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 8,287,871 | Methods of Inducing Cell Death of an Activated T Cell with ANTI-PSGL-1 Antibodies Formerly held Term ended Term ended May 10, 2025 · High confidence | Term ended | Term ended May 10, 2025 | High confidence |
| US 8,663,641 | Anti-PSGL-1 antibodies Formerly held Term ended Ended no later than May 10, 2025 · USPTO record | Term ended | Ended no later than May 10, 2025 | USPTO record |
| US 10,030,075 | Methods of Treating with ANTI-PSGL-1 Antibodies Formerly held Term ended Term ended May 10, 2025 · High confidence | Term ended | Term ended May 10, 2025 | High confidence |
| US 9,631,019 | Methods of Treating GVHD and Transplant Rejection with ANTI-PSGL-1 Antibodies Formerly held Lapsed on the fee record Ended Apr 25, 2025 · High confidence | Lapsed on the fee record | Ended Apr 25, 2025 | High confidence |
| US 8,361,472 | Anti-PSGL-1 antibodies Formerly held Lapsed on the fee record Ended Jan 29, 2025 · USPTO record | Lapsed on the fee record | Ended Jan 29, 2025 | USPTO record |
| US 8,828,397 | ANTI-PSGL-1 Antibodies and Methods of Inducing Cell Death of an Activated T Cell Formerly held Lapsed on the fee record Ended Sep 9, 2022 · High confidence | Lapsed on the fee record | Ended Sep 9, 2022 | High confidence |
| US 7,744,888 | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies Formerly held Lapsed on the fee record Ended Jun 29, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2022 | USPTO record |
| US 8,628,775 | Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds Lapsed on the fee record Ended Jan 14, 2022 · USPTO record | Lapsed on the fee record | Ended Jan 14, 2022 | USPTO record |